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Abstract
Background: Mesenchymal stem cells (MSCs)-based regenerative therapy is currently regarded
as an alternative approach to salvage the acute myocardial infarcted hearts. However, the efficiency
of MSCs transplantation is limited by lower survival rate of engrafted MSCs. In previous study, we
found that 1.0 μg/ml Lipopolysaccharide (LPS) could protect MSCs against apoptosis induced by
oxidative stress and meanwhile enhance the proliferation of MSCs. Therefore, in the present study,
we firstly preconditioned MSCs with 1.0 μg/ml LPS, then transplanted MSCs into ischemic
myocardium, and observed the survival and cardiac protective capacity of MSCs in a rat model of
acute myocardial infarction. Furthermore, we tried to explore the underlying mechanisms and the
role of Toll-like receptor-4 (TLR4) in the signal pathway of LPS-induced cardiac protection.
Methods and results: Acute myocardial infarction model was developed by left anterior
descending coronary artery ligation. 60 rats were divided into 4 groups randomly and given an
intramyocardial injection of one of the following treatments: 30 μl PBS (control group), 3 × 106 wild
MSCs/30 μl (wMSCs group), 3 × 106 LPS-preconditioned wild MSCs/30 μl (LPS-wMSCs group), or
3 × 106 LPS-preconditioned TLR4 gene deleted MSCs/30 μl (LPS-tMSCs group). After 3 weeks,
LPS-preconditioned wild MSCs transplantation ameliorated cardiac function and reduced fibrosis
of infarcted myocardium. Vascular density was markedly increased in LPS-wMSCs group compared
with other three groups. Survival rate of engrafted MSCs was elevated and apoptosis of
myocardium was reduced in infarcted heart. Expression of vascular endothelial growth factor
(VEGF) and phospho-Akt was increased in the infarcted myocardium after transplantation of LPS-
preconditioned MSCs.
Conclusion: LPS preconditioning enhanced survival of engrafted MSCs, stimulated expression of
VEGF and activated PI3K/Akt pathway. LPS preconditioning before MSCs transplantation resulted
in superior therapeutic neovascularization and recovery of cardiac function. LPS preconditioning
provided a novel strategy in maximizing biologic and functional properties of MSCs.
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Background
Despite the clinical success of reperfusion therapy, a large
proportion of patients develop myocardial necrosis, ven-
tricular remodelling and resultant congestive heart failure
after acute myocardial infarction (AMI) [1]. Mesenchymal
stem cells (MSCs)-based regenerative therapy is currently
regarded as an alternative approach to salvage the MI
hearts [2-4]. However, a major challenge to MSCs therapy
is that transplanted cells undergo apoptosis, as they are
exposed to an extremely harsh microenvironment in the
infarcted heart. The efficiency of MSCs transplantation is
limited by lower survival rate of MSCs [5,6]. Therefore,
protection of MSCs against apoptosis is critical for suc-
cessful cellular therapy. Novel strategies are being devel-
oped to maximize biologic and functional properties of
MSCs, such as the preparation of cells in special bioscaf-
folds [7], preconditioning of cells in culture [8,9], and
genetic transfection [10,11].
Toll-like receptors (TLRs) are a class of molecules which
play an important role in the innate immune system for
the recognition of pathogen-associated molecular pat-
terns by immune cells, initiating a primary response
toward invading pathogen and recruitment of the adap-
tive immune response [12-14]. Recent research found that
MSCs express TLR molecules 1 to 8. Pam3Cys, a proto-
typic ligand for TLR2, induced proliferation of MSCs and
regulated their differentiation [15]. Lipopolysaccharide
(LPS) is the antigenic component of the gram-negative
bacterial cell wall and is known as the ligand of Toll-like
receptor-4 (TLR4). In our previous study, we found that
1.0  μg/ml LPS could protect MSCs against apoptosis
induced by oxidative stress, and enhance the proliferation
of MSCs [16]. However, whether LPS could protect MSCs
against apoptosis and increase the survival rate of
engrafted MSCs in the infarcted myocardium need to be
further investigated.
In the present study, we preconditioned MSCs with 1.0
μg/ml LPS, then transplanted them into ischemic myocar-
dium, and observed the survival and cardiac protective
capacity of MSCs in a rat acute myocardial infarction
model. Furthermore, we tried to explore potential mecha-
nisms and the role of TLR4 in the signal pathway of LPS-
induced cardiac protection.
Methods
Animal preparation
Adult male C57BL/10J mice (wild type, 68 weeks, 2530 g)
and C57BL/10ScNJ mice (TLR4 gene deleted type, 68
weeks, 2530 g) were provided by the Model Animal
Research Centre of Nanjing University (Nanjing, China).
Adult female Wistar rats (210250 g) were purchased from
Slac company (Shanghai, China). The procedure was per-
formed in accordance with the "Guide for the Care and
Use of Laboratory Animals" (NIH Publication No. 85-23,
National Academy Press, Washington, DC, revised 1996).
The study protocol was approved by the Animal Care and
Use Committee of Nanjing Medical University.
Isolation, expansion and labeling of MSCs
Wild MSCs (wMSCs) were harvested from male C57BL/
10J mice, and TLR4 gene deleted MSCs (tMSCs) were iso-
lated from male C57BL/10ScNJ mice, respectively. Isola-
tion of MSCs from mice was performed as previously
described with minor modifications [17]. Briefly, mice
were sacrificed humanely and femurs were aseptically har-
vested. Whole marrow cells were obtained by flushing the
bone marrow cavity with low glucose Dulbecco's Modi-
fied Eagle's Medium (L-DMEM, Hyclone, USA). Cells
were centrifuged at 1000 × g for 5 minutes and the super-
natant was removed. The cell pellet was then re-sus-
pended with L-DMEM supplemented with 10% fetal
bovine serum (FBS, Hyclone, USA), 100 U/ml penicillin
(Invitrogen), 100 U/ml streptomycin (Invitrogen), and
incubated at 37°C in a 5% CO2 atmosphere. After 24
hours, non-adherent cells in suspension were discarded
and culture media was replaced every three or four days
thereafter. When MSCs reached 80%90% of confluence,
they were trypsinized by the addition of 0.25% trypsin-
EDTA (Sigma-Aldrich, USA), and then re-plated in culture
flasks at a density of 5 × 104/cm2. Cells between passages
4 and 5 were utilized for experiment. Cells were con-
firmed to be MSCs by cell surface markers with flow
cytometry analysis: CD14-; CD29+; CD34-; CD44+; CD45-
, and CD105+.
To label MSCs with 1,1'-dioctadecyl-3,3,3'3'-testramethyl-
indo-carbocyanine perchlorate (DiI), 2 μg/ml DiI was
added to MSCs suspension and incubated at 37°C for 5
minutes, then at 4°C for 15 minutes with occasional mix-
ing. MSCs labeled with DiI were washed 3 times with PBS.
All cells were kept frozen until use.
VEGF assessment by Enzyme-link immunosorbent assay 
(ELISA)
wMSCs and tMSCs were plated in 24 well plates respec-
tively at a concentration of 1 × 105 cells/well/ml and incu-
bated with serum-free L-DMEM. After 24 hours, wMSCs
and tMSCs were stressed with different concentrations of
LPS (0 μg/ml, 0.01 μg/ml, 0.1 μg/ml, 1.0 μg/ml, 10 μg/
ml) respectively. Cells were subsequently exposed to 5
nmol/L pyrrolidine dithiocarbamate (PDTC) or not,
which was an inhibitor of NF-κB. After 48 hours of incu-
bation, supernatants were harvested. Concentration of
vascular endothelial growth factor (VEGF) in supernatants
was determined by VEGF ELISA kits (R&D Systems)
according to the instruction of the manufacturer. Experi-
ments were repeated three times for verification of results.Journal of Biomedical Science 2009, 16:74 http://www.jbiomedsci.com/content/16/1/74
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Myocardial infarction model and MSCs transplantation
Female Wistar rats were anesthetized with ketamine (100
mg/kg) by intraperitoneal injection and mechanically
ventilated. Under a sterile condition, the heart was
exposed through a left thoracotomy, and the left anterior
descending coronary artery was ligated at just below the
atrioventricular border. Successful ligation was identified
by cyanosis of the left ventricular anterior wall and ST-T
elevation on electrocardiogram. The rats were allowed to
recover under care. Before transplantation, LPS-precondi-
tioned nMSCs and tMSCs were exposed to 1.0 μg/ml LPS
for 48 hours and collected. 80 rats were used in our exper-
iment. 12 rats died after AMI, and 8 rats died within 7 days
after AMI. One week after AMI, remaining 60 rats were
divided into 4 groups randomly and given an intramyo-
cardial injection with one of the following treatments: 30
μl PBS (control group, n = 15), 3 × 106 wMSCs/30 μl
(wMSCs group, n = 15), 3 × 106  LPS-preconditioned
wMSCs/30 μl (LPS-wMSCs group, n = 15), or 3 × 106 LPS-
preconditioned tMSCs/30 μl (LPS-tMSCs group, n = 15).
3 × 106 MSCs were injected into two sites of the myocar-
dium with a bent 26-gauge needle, one within the infarct
area and the other in the myocardium bordering the
ischemic area. At the end of experiment, the chest was
closed, and animals were weaned from the ventilator and
allowed to recover. Three weeks after cells transplantation,
the rats were sacrificed and hearts from different groups
were harvested for the following experiments.
Functional assessment by echocardiography
Three weeks after cells transplantation, the rats were
undergone cardiac function assessment by transthoracic
echocardiography with 12-MHz phased-array transducer
(Hewlett Packard). The heart was imaged in the cross-sec-
tional mode in parasternal long- and short-axis views of
the left ventricle (LV). Average LV end-diastolic diameter
(LVDd), LV end-systolic diameter (LVDs), LV ejection
Fraction (LVEF) and LV fractional shortening (FS) were
measured from three consecutive cardiac cycles. All meas-
urements were done by two experienced echocardiogra-
pher who were blinded to treatment assignment.
Fibrosis assessment by Masson's trichrome
To detect fibrosis in cardiac muscle, the LV myocardium
(n = 5, each) was fixed in 4% paraformaldehyde, cut trans-
versely, embedded in paraffin, and stained with Masson's
trichrome. Ten anterolateral sections from each heart were
evaluated in their entirety and quantified. Fibrosis was
determined by measuring the collagen area as a propor-
tion of the total area under observation. These morpho-
metric studies were performed by two examiners who
were blinded to treatment assignment.
Evaluation of survival of engrafted MSCs
Hearts were harvested, soaked in 30% sucrose in PBS over-
night at 4°C and then embedded in Tissue-Tak OCT
(Sakura). Serial 20 μm thick sections were cut at -20°C
and observed under fluorescence microscope (Leica
Microsystems, Wetzlar, Germany). Engrafted MSCs were
identified by the presence of DiI-labeled cells.
Because the engrafted cells were harvested from male
mice, the survival rate of the transplanted MSCs could be
examined by the quantitation of sry  (sex-determining
region of Y-chromosome) gene in the female rat heart,
using real-time fluorescence TaqMan PCR 3 weeks after
cells transplantation. Briefly, after the animals were killed,
hearts from different groups were removed and DNA was
isolated using Genomic DNA Isolation Kit (QIAGEN).
Specific primers were designed based on the GeneBank
sequences of the sex-determining region of the Y
chromosome5 of the rat (sense 5'-GAGGCACAAGTT-
GGCTCAACA-3'; antisense 5'-CTCCTGCAAAAAG-
GGCCTTT-3') [18]. Quantitative PCR was performed and
analyzed as described previously [19].
TUNEL assay
Three weeks after cells transplantation, apoptotic cardio-
myocytes in the infarcted heart were evaluated by TUNEL
assay using an in situ Cell Death Detection Kit (Roche,
Germany) according to the manufacturer's instructions.
Apoptotic cells were identified by brown colour in their
nuclei. Tissue sections were examined microscopically
and the percentage of apoptotic cells per total cells was
determined in eight randomly chosen fields.
Immunohistochemical assay
Rats from each group were sacrificed 3 weeks after cells
transplantation. Heart muscle samples were fixed in 4%
paraformaldehyde, embedded in paraffin, and sectioned
at 5 μm intervals. Endothelial cells were identified by the
expression of von Willebrand Factor (vWF). Immunohis-
tology was performed with specific primary antibody
against vWF (1:100, abcom). Five fields on the slide pre-
senting infarcted area from each heart were randomly cho-
sen for counting stained blood vessels under microscope
(×100, Olympus CX-21). The blood vessel density was
expressed as vessel number/field.
Western blot analysis of VEGF, Akt and phospho-Akt
Cytoplasmic protein was prepared from heart tissue and
immunoblot was performed as described previously [20].
Protein was analyzed using 10% sodium dodecyl sul-
phate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to nitrocellulose membranes (Bio-Rad).
Membranes were then incubated with primary antibodies
including VEGF (1:1000, Cell Signaling), Akt (1:1000,
Cell Signaling), phosphorylated Akt (1:1000, Cell Signal-Journal of Biomedical Science 2009, 16:74 http://www.jbiomedsci.com/content/16/1/74
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ing) and β-actin (1:5000, Sigma) at 4°C overnight respec-
tively. The membranes were then incubated with
peroxidase labeled secondary antibody (1:1000, Santa
Cruz, USA) at 37°C for 2 hours. Signals were detected by
enhanced chemiluminescence (Amersham, USA). Densit-
ometric analysis for the blots was performed with NIH
image software. Experiments were repeated 6 times for
verification of results.
Statistical analysis
Data are expressed as mean ± SEM and analysed with
SPSS11.0 statistical software. Differences between groups
were analyzed by Student t test or Fisher's exact test, where
appropriate. Statistical significance was set at < 0.05 level.
Results
LPS promoted VEGF secretion of MSCs in vitro
VEGF concentration was higher in the groups following
LPS treatment than that without it (concentration of LPS
is 0, 0.01, 0.1, 1.0, 10.0 μg/ml and corresponding concen-
tration of VEGF is 615.5 ± 36.7, 892.7 ± 35.3, 1163 ± 55.8,
1387 ± 48.1, 938.3 ± 35.2 pg/105cells). VEGF concentra-
tion was the highest after incubation with 1.0 μg/ml LPS
for 48 hours (Fig 1A). In the presence of NF-κB inhibitor-
PDTC, LPS stimulation induced increase in VEGF expres-
sion was reduced (718.3 ± 32.7 vs.1387 ± 48.1 pg/
105cells, respectively, P < 0.01). LPS induced stimulation
of VEGF expression in tMSCs is less than that of wild
MSCs (760 ± 38.2 vs.1387 ± 48.1 pg/105cells, respectively,
P < 0.01, Fig 1B).
LPS-preconditioned MSCs improved cardiac function
Three weeks after transplantation, LPS-wMSCs group had
greater LVEF than wMSCs group and LPS-tMSCs group (P
< 0.01). These three groups had significantly greater LVEF
than control group (P < 0.01), whereas without difference
between wMSCs group and LPS-tMSCs group. Other
echocardiographic parameters, including FS, LVDd and
LVDs, showed similar difference among groups (table 1).
The results suggested that an improved cardiac function
was obtained by injection of LPS-pretreated wMSCs.
VEGF concentration in the culture supernant of MSCs Figure 1
VEGF concentration in the culture supernant of MSCs. ELISA analysis of supernatant after stimulation of LPS is shown. 
Wild MSCs were exposed to increasing doses of LPS for 48 hours. VEGF concentration increased after LPS treatment and 
VEGF concentration was the highest after incubation with 1.0 μg/ml LPS. B. In the presence of NF-κB inhibitor-PDTC, LPS 
stimulation caused a subsequent decrease in VEGF expression compared with that without NF-κB inhibition. LPS stimulation 
on tMSCs caused an obvious decrease in VEGF expression compared with that of wild MSCs. (a. VEGF concentration of 
wMSCs without stimulation of LPS; b. VEGF concentration of wMSCs with 1.0 μg/ml LPS stimulation; c. VEGF concentration of 
wMSCs with stimulation of 1.0 μg/ml LPS and 5 nmol/L PDTC; d. VEGF concentration of TLR4 gene deleted MSCs with stimu-
lation of 1.0 μg/ml LPS) Data are mean ± SEM. *P < 0.05 vs. control group, #P < 0.05 vs. NF-κB inhibition and TLR4 deletion 
groups.Journal of Biomedical Science 2009, 16:74 http://www.jbiomedsci.com/content/16/1/74
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LPS-preconditioned MSCs reduced the fibrosis of infarcted 
myocardium
Masson's trichrome staining demonstrated modest myo-
cardial fibrosis in the control group (11.1 ± 0.8%).
wMSCs and LPS-preconditioned tMSCs significantly
reduced fibrosis (8.3 ± 0.5% and 8.9 ± 0.6%, P < 0.05),
whereas LPS-preconditioned wMSCs reduced fibrosis fur-
ther (6.6 ± 0.5%, P < 0.05). There was no statistical signif-
icance between wMSCs group and LPS-tMSCs group (Fig
2).
Survival of transplanted cells
Many engrafted MSCs were detected along the track of
needle injection by the presence of DiI-labeled cells. After
3 weeks, a decrease in the absolute number of engrafted
cells was observed in the three MSCs transplanted groups,
and transplanted cells were not found in control group
(Fig 3A). However, real-time PCR for sry gene showed that
the survival rate of donor cells in LPS-wMSCs group was
significantly higher (1.89 ± 0.10-folds) compared with
that in wMSCs group (1 fold, P < 0.01). The survival of the
donor cells in LPS-tMSCs group was higher (1.09 ± 0.04-
folds) than that in wMSCs group, but did not show signif-
icant statistical difference (Fig 3B). These results indicate
that LPS preconditioning can enhance the survival of
engrafted MSCs in the infarcted heart.
Table 1: Cardiac function 3 weeks after surgery.
LVDd(cm) LVSd(cm) LVEF(%) FS(%)
control group 0.78 ± 0.02 0.68 ± 0.03 30.66 ± 1.56 11.21 ± 0.45
wMSCs group 0.70 ± 0.02a 0.54 ± 0.03a 51.18 ± 0.97a 21.13 ± 0.55a
LPS-wMSCs group 0.68 ± 0.02a, b, c 0.46 ± 0.02a, b, c 65.43 ± 1.25a, b, c 25.88 ± 0.54a, b, c
LPS-tMSCs group 0.71 ± 0.02a 0.57 ± 0.02a 50.38 ± 1.29a 20.91 ± 0.71a
Note: aP < 0.01 vs. control group; bP < 0.01 vs. wMSCs group; cP < 0.01 vs. LPS-tMSCs group.
LPS-preconditioned MSCs reduced the fibrosis of infarcted myocardium Figure 2
LPS-preconditioned MSCs reduced the fibrosis of infarcted myocardium. Representative samples of myocardial 
fibrosis stained with Masson's trichrome (× 400). B. Quantitative analysis of myocardial fibrosis. Data are mean ± SEM. * P < 
0.05 versus control group; #P < 0.05 versus wMSCs group; §P < 0.05 versus LPS-tMSCs group.Journal of Biomedical Science 2009, 16:74 http://www.jbiomedsci.com/content/16/1/74
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LPS-preconditioned MSCs transplantation reduced the 
apoptosis of myocardium
TUNEL-positive nuclei staining was detectable in inf-
arcted heart muscle cells in both control and experimental
groups (Fig 4A). The percentage of TUNEL-positive cells
markedly decreased in LPS-wMSCs group (14.8 ± 1.5%),
wMSCs group (23.4 ± 2.1%) and LPS-tMSCs group (23.2
± 1.6%), compared with that in control group (34.3 ±
1.7%, P < 0.01). The percentage of apoptotic cells was the
lowest in LPS-wMSCs group among the four groups (P <
0.01) (Fig 4B).
LPS-preconditioned MSCs transplantation increased 
vascular density
Immunostaining of the infarcted myocardium for vWF
expression showed an augmentation of neovasculariza-
tion in the cells-transplanted groups (Fig 5A). 3 weeks
after cells or PBS injection, blood vessel density per fields
in the infarct or peri-infarct zones was significantly greater
in LPS-wMSCs group (45.3 ± 4.3, P < 0.01) than that in
wMSCs group (32.2 ± 3.1) and LPS-tMSCs group(31.1 ±
2.7). Control group (22.8 ± 1.9, P < 0.01) had the lowest
vessel density among the 4 groups (Fig 5B).
LPS preconditioning enhanced the survival of engrafted MSCs Figure 3
LPS preconditioning enhanced the survival of engrafted MSCs. A. Engrafted MSCs were detected by the presence of 
DiI-labeled cells (red) and cells were not found in control group(× 200). B. Real-time PCR for sry gene in the female heart tis-
sue samples at 3 weeks after sex-mismatched cell transplantation. The fold change in sry gene expression in different groups 
was calculated. The result showed significantly higher survival rate of the engrafted cells in the LPS-wMSCs group compared 
with that in wMSCs group and LPS-tMSCs group. Data are mean ± SEM. *P < 0.01 versus wMSCs group; #P < 0.01 versus LPS-
tMSCs group.Journal of Biomedical Science 2009, 16:74 http://www.jbiomedsci.com/content/16/1/74
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LPS-preconditioned MSCs transplantation increased 
expression of VEGF and phosphorylated Akt in vivo
To determine if LPS preconditioning improves VEGF
secretion  in vivo, protein was collected from infarcted
myocardium. Western blot analysis showed that levels of
VEGF were increased in cells transplanted groups com-
pared with that in control group (P < 0.05). LPS-wMSCs
group had the highest VEGF secretion among the four
groups (Fig 6A). To investigate whether LPS precondition-
ing could induce the activation of PI3K/Akt signalling in
the myocardium, we examined the level of phospho-Akt
in the myocardium. As shown in Fig 6B, significant
increase in the ratio of phospho-Akt/Akt was observed in
the cells-transplanted groups compared with that in con-
trol group (P < 0.05). The ratio of phospho-Akt/Akt was
the highest in the LPS-wMSCs group among the four
groups (P < 0.05). Thus, LPS-pretreated MSCs transplanta-
tion increased expression of VEGF and phospho-Akt in
infarcted myocardium.
Discussion
The main findings of this study are 1) LPS precondition-
ing can improve the survival of MSCs, promote expression
of VEGF and phospho-Akt in infarcted myocardium; 2)
LPS-preconditioned MSCs transplantation can enhance
cardiac function, reduce apoptosis of myocardium,
inhibit fibrosis and elevate vascular density after MI; 3)
TLR4 plays an important role in the signal pathway of
LPS-induced cardiac protection.
Although few reports have quantified stem cell survival
after transplantation, donor stem cell survival may be as
LPS-preconditioned MSCs transplantation reduced the apoptosis of myocardium Figure 4
LPS-preconditioned MSCs transplantation reduced the apoptosis of myocardium. A. Representative photo-micro-
graphs of TUNEL-positive nuclei staining (brown) in ischemic cardiac muscle cells (× 400). B. The percentage of apoptotic cells 
was the lowest in LPS-wMSCs group among the four groups. Data are mean ± SEM. *P < 0.01 versus control group; #P < 0.01 
versus wMSCs group; §P < 0.01 versus LPS-tMSCs group.Journal of Biomedical Science 2009, 16:74 http://www.jbiomedsci.com/content/16/1/74
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low as 1%5% 48 hours after transplantation [2,6], possi-
bly due to a hostile, nutrient-deficient, inflammatory
environment within damaged myocardium. This low sur-
vival may limit the sustained reparative capacity of stem
cells in vivo. Enhanced survival of transplanted stem cells
may increase their cytoprotective efficacy. Our previous
study had suggested that 1.0 μg/ml LPS could protect
MSCs from oxidative stress-induced apoptosis and
improve the survival of MSCs via TLR4 and PI3K/Akt
pathway. After pretreated by 1.0 μg/ml LPS, MSCs
strengthened the power against oxidative stress and
inflammatory environment in infarcted area. In present
study, we also found that survival ratio of transplanted
MSCs was elevated in infarcted myocardium after LPS pre-
conditioning by detecting the sry gene in the donor heart.
Recent studies have indicated that paracrine mechanism,
carried out by the cells through the release of soluble cel-
LPS-preconditioned MSCs transplantation increased vascular density Figure 5
LPS-preconditioned MSCs transplantation increased vascular density. A. Endothelial cells were stained with antibody 
against vWF, and blood vessel numbers were counted (× 100). B. Five fields were randomly selected from each sample (n = 8), 
and blood vessel density is shown as the vessel number/field. Data are mean ± SEM. *P < 0.01 vs. control group; #P < 0.01 vs. 
wMSCs group; §P < 0.01 vs. LPS-tMSCs group.Journal of Biomedical Science 2009, 16:74 http://www.jbiomedsci.com/content/16/1/74
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lular factors, might be a critical mechanism of tissue repair
and functional improvement after MSCs transplantation
[21]. VEGF is a crucial paracrine factor in MSCs-mediated
cardioprotection. In addition to its potent angiogenic
function, VEGF can stimulate proliferation, delay senes-
cence, suppress apoptosis and promote survival of various
cells [22,23]. It has reported that MSCs exposed to LPS
could increase expression of VEGF [24,25]. In in vitro
study, we demonstrated that a significant level of VEGF
was detected in the culture medium of LPS-treated MSCs.
In in vivo study, Western bolt analysis also implied that
LPS-preconditioning MSCs transplantation released more
VEGF in infarcted myocardium than that without LPS pre-
conditioning. As a result of VEGF secretion, the vascular
density was increased in LPS-preconditioning group than
that without LPS-preconditioning. Furthermore, the pro-
tected cardiac function and the reduced apoptosis of myo-
cardium in infarcted heart were also related with
expression of VEGF. Thus, we demonstrated that LPS-pre-
conditioning promoted the release of VEGF, which in turn
improved the effect of MSCs transplantation in the inf-
arcted area.
Phosphoinositide 3-kinase (PI3K) and its downstream
target serine/threonine kinase Akt are now recognized as
one of the most critical pathways in regulating cellular
activation, inflammatory responses and apoptosis
[26,27]. Activation of PI3K/Akt-dependent signalling has
been shown to prevent cardiac myocyte apoptosis and
protect the myocardium from AMI [10,28]. Akt is acti-
vated by site-specific phosphorylation. In our study, we
found that the level of phosphor-Akt was elevated and the
apoptosis of myocardium was reduced in LPS-wMSCs
group compared with that in wMSCs group. So we dem-
onstrated that LPS-preconditioned MSCs resulted in sig-
nificantly increased levels of phospho-Akt in the
myocardium which positively correlated with cardiopro-
tection. Our results indicated that effect of LPS-condi-
tioned MSCs transplantation was mediated partially
through a PI3K/Akt-dependent mechanism.
TLRs are a conservative family of receptors that recognize
pathogen-associated molecular patterns and promote the
activation of immune cells [29,30]. Recent studies have
shown that the heart expresses TLR4 mRNA and protein
[31], and TLR4 plays a role in myocardial dysfunction
LPS-preconditioned MSCs transplantation increased expression of VEGF and phosphorylated Akt protein in vivo Figure 6
LPS-preconditioned MSCs transplantation increased expression of VEGF and phosphorylated Akt protein in 
vivo. Representative Western blots for expression of VEGF. Corresponding β-actin blots are shown as a control for sample 
loading. Bar graph on right shows quantitation. The protein levels for each sample were determined as a ratio to their corre-
sponding β-actin levels. B. Representative Western blots for expression of phospho-Akt, Akt. Total Akt served as a loading 
control. Bar graph on right shows quantitation. The protein levels of phospho-Akt for each sample were determined as a ratio 
to their corresponding Akt levels. Data are mean ± SEM. *P < 0.05 versus control group; #P < 0.05 versus wMSCs group; §P < 
0.05 versus LPS-tMSCs group.Journal of Biomedical Science 2009, 16:74 http://www.jbiomedsci.com/content/16/1/74
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during bacterial sepsis [32,33]. However, a low dose of
LPS (0.2 mg/kg) preconditioning induced cardioprotec-
tion in a rodent model of ischaemia/reperfusion injury
[34]. Preconditioning, injury-induced protection from
subsequent injury, has been proven to be a powerful form
of cardioprotection. Jiang et al. [35] preconditioned MSCs
with hypoxia, transplanted the stem cells into ischemic
myocardium, and observed enhanced survival and cyto-
protective capacity. Guo et al. [36] preconditioned MSCs
with IGF-1 and found enhancement of the number of
MSCs attracted into the infarcted heart. In the present
study, we found LPS-preconditioning could enhance sur-
vival of MSCs, stimulate expression of VEGF and activate
PI3K/Akt pathway. Conversely, TLR4-deleted MSCs
(tMSCs) released less VEGF and exerted less functions in
reducing apoptosis of myocardium than LPS-precondi-
tioning wMSCs. TLR-mediated signalling activates NF-κB,
which plays a critical role in regulating expression of
genes, such as VEGF. In our in vitro study, we found that
NF-κB inhibition prevented secretion of VEGF under the
LPS condition. So we concluded that TLR4/NF-κB signal-
ling pathway played an important role in cardioprotec-
tion performed by LPS preconditioning. LPS
preconditioning could promote expression of other
cytokines, such as fibroblast growth factor 2 (FGF2), insu-
lin-like growth factor 1 (IGF-1), and hepatocyte growth
factor (HGF) [25]. The exact effects of these cytokines in
infarcted heart need a further investigation.
In conclusion, this study demonstrates that LPS precondi-
tioning can enhance survival of MSCs, stimulate expres-
sion of VEGF, and activate PI3K/Akt pathway. LPS
preconditioning before MSCs transplantation leads to
superior therapeutic neovascularization and recovery of
cardiac function. Therefore, LPS preconditioning provides
a novel strategy in maximizing biologic and functional
properties of MSCs.
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